10, article 1046, 24 May 2019, Rodrigues, Vanessa Fernandes, et al
Systemic glutathione deficiency in symptom-free HIV-seropositive individuals
Abstract P4-12-17: Pre-clinical data and phase I design for PQ-203: a novel peptide-drug conjugate (PDC) targeting the SORT1 receptor in hormone receptor Triple Negative Breast Cancer (TNBC)
For individuals on a weight loss journey using injectable medications such as Mounjaro (tirzepatide) or Wegovy (semaglutide), the holy month often requires thoughtful planning to balance health needs with fasting
In many cases, patients can switch directly, though the timing and starting dose of the new medication will depend on your current tirzepatide dose and how long since your last injection
49 Phase 3 trials SYNCHRONISE-1 (in people without diabetes) and SYNCHRONISE-2 (in people with diabetes) are ongoing to assess the efficacy and durability of weight loss with 3.6 and 6 mg doses over 76 weeks (clinical trial numbers NCT06066515 and NCT06066528)